Phase III Trial in Acute Promyelocytic Leukemia Patients (APL0406)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00482833 |
|
Recruitment Status :
Completed
First Posted : June 5, 2007
Last Update Posted : October 12, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Leukemia | Drug: arsenic trioxide Drug: idarubicin Drug: mercaptopurine Drug: methotrexate Drug: all-trans retinoic acid Drug: all-trans retinoic acid (ATRA) | Phase 3 |
-
Arm I:
- Induction therapy: Patients receive oral tretinoin twice daily and arsenic trioxide IV over 2 hours on days 1-60. Patients achieving hematological complete remission go on to receive consolidation therapy.
- Consolidation therapy: Patients receive oral tretinoin twice daily on days 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide IV over 2 hours on days 1-5 in weeks 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses.
-
Arm II:
- Induction therapy: Patients receive tretinoin as in arm I induction therapy and idarubicin IV over 20 minutes on days 2, 4, 6, and 8. Patients achieving hematological complete remission go on to receive consolidation therapy.
- Consolidation therapy: Patients receive oral tretinoin twice daily on days 1-45, idarubicin IV over 20 minutes on days 1-4 and day 31, and mitoxantrone hydrochloride IV over 30 minutes on days 16-20.
Marrow samples are collected after completion of consolidation therapy and analyzed by reverse transcriptase-PCR for molecular remission. Patients achieving molecular remission (PML-RARa negative) go on to receive maintenance therapy.
- Maintenance therapy: Patients receive oral mercaptopurine once daily and methotrexate intramuscularly once weekly for 3 months. Treatment with mercaptopurine and methotrexate repeats every 3 months for 7 courses. After completion of course 1 of mercaptopurine and methotrexate, patients receive oral tretinoin once daily on days 1-15*. Treatment with tretinoin repeats every 3 months for 6 courses.
NOTE: *Patients do not receive mercaptopurine and methotrexate during tretinoin administration.
After completion of study therapy, patients are followed periodically for 5 years.
As of 14th September 2010, all patients needed to evaluate the primary endpoint (162 patients) have been recruited but the trial accrual continued in order to assess one secondary outcome (QoL)."
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 276 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia |
| Study Start Date : | August 2007 |
| Actual Primary Completion Date : | September 2012 |
| Actual Study Completion Date : | October 17, 2019 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: ARM A - ATO/ATRA |
Drug: arsenic trioxide
Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days. Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28). Drug: all-trans retinoic acid (ATRA) Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days. Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26). |
| Active Comparator: ARM B - ATRA |
Drug: idarubicin
Induction Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion . If no hematological CR is achieved by 60 days after start of induction, patient will go off-study. Consolidation 1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4. 3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1. Drug: mercaptopurine Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period Drug: methotrexate Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period. Drug: all-trans retinoic acid Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days. Consolidation
Maintenance therapy ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed. |
- Event-free survival [ Time Frame: At maximum 3.5 years from study entry ]As of 14th september 2010, all patients needed to evaluate the primary endpoint have been recruited.
- Rate of hematological complete remission [ Time Frame: At maximum 60 days from induction therapy start ]
- Overall survival rate [ Time Frame: At 2 years from study entry ]
- Rate of cumulative incidence of relapse [ Time Frame: At 2 years from study entry ]
- Incidence of hematological and non-hematological toxicity episodes during treatment as assessed by CTC-NCI [ Time Frame: At maximum 60 days from induction therapy start and at maximum 225 days from consolidation therapy start ]
- Rate of molecular remission after 3rd consolidation course [ Time Frame: At maximum 225 days grom consolidation therapy start ]
- Assessment of acute promyelocytic leukemia/RARa transcript level reduction after induction and during consolidation therapy [ Time Frame: At maximum 60 days from induction therapy start and at maximum 225 days from consolidation therapy start ]
- Quality of life at the end of induction therapy and at the end of the 3rd consolidation course [ Time Frame: At maximum 60 days from induction therapy start and at maximum 225 days from consolidation therapy start ]
- Event free survival [ Time Frame: At 2 years from study entry ]
- Total hospitalization days during study therapy [ Time Frame: At maximum 3.5 years from study entry ]
- Event-free survival rate in the two arms [ Time Frame: At 2 years from study entry ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion criteria
- Signed written informed consent according to IGH/EU/GCP and national local laws
- Newly diagnosed APL by cytomorphology, confirmed also by molecular analysis*.
- Age ≤18 < 71 years
- WHO performance status 0 -2 included
- WBC at diagnosis ≤ 10 x 109/L
- Serum total bilirubin ≤ 3.0 mg/dL (≤ 51µmol/L)
- Serum creatinine ≤ 3.0 mg/dL (≤ 260 µmol/L)
The confirmation of diagnosis at genetic level (microspeckled PML nuclear distribution by PGM3 monoclonal antibody and/or PML/RARa fusion by RT-PCR and/or demonstration of t(15;17) by karyotyping) will be mandatory for patient eligibility. However, in order to avoid delay in treatment initiation, patients can be randomised on the basis of morphologic diagnosis only and before the results of genetic tests are available.
Exclusion criteria
- Age < 18 and ≥ 71
- WBC at diagnosis > 10 x 109/L
- Other active malignancy at time of study entry
- Lack of diagnostic confirmation at genetic level
- Significant arrhythmias, EKG abnormalities (*see below) or neuropathy
- Other cardiac contraindications for intensive chemotherapy (L-VEF <50%)
- Uncontrolled, life-threatening infections
- Severe non-controlled pulmonary or cardiac disease
-
Women who are either pregnant or breast feeding, or of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they meet one of the following definitions:
- Amenorrhea;
- post surgical bilateral oophorectomy with or without hysterectomy;
- using a highly effective method of birth control (defined as those which result in a failure rate less than 1% per year) when used consistently and correctly such as implants, injectables, oral contraceptives, IUDs, sexual abstinence or vasectomized partner.
- Concomitant severe psychiatric disorder
-
HIV positivity
*EKG abnormalities:
- Congenital long QT syndrome;
- History or presence of significant ventricular or atrial tachyarrhythmia
- Clinically significant resting bradycardia (<50 beats per minute)
- QTc > 450 msec on screening EKG (using the QTcF formula detailed on page 18)
- Right bundle branch block plus left anterior hemiblock, bifascicular block
- Use of other investigational drugs at the time of enrolment or within 30 days before study entry
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00482833
Show 110 study locations
| Study Chair: | Francesco Lo Coco, MD | Azienda Ospedaliera Universitaria Policlinico Tor Vergata |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| ClinicalTrials.gov Identifier: | NCT00482833 |
| Other Study ID Numbers: |
APL0406 GIMEMA-SAL-APL0406 EUDRACT-2006-006188-22 |
| First Posted: | June 5, 2007 Key Record Dates |
| Last Update Posted: | October 12, 2022 |
| Last Verified: | October 2022 |
|
adult acute promyelocytic leukemia (M3) adult acute myeloid leukemia with t(15;17)(q22;q12) untreated adult acute myeloid leukemia |
|
Leukemia Leukemia, Promyelocytic, Acute Neoplasms by Histologic Type Neoplasms Hematologic Diseases Leukemia, Myeloid, Acute Leukemia, Myeloid Methotrexate Mercaptopurine Idarubicin Tretinoin Arsenic Trioxide Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents |
Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Nucleic Acid Synthesis Inhibitors Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors |